Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.

@article{Liao2004ImmunogenicityOC,
  title={Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.},
  author={H. X. Liao and S. Munir Alam and John R. Mascola and James Robinson and Benjiang Ma and David C. Montefiori and Maria E Rhein and Laura L Sutherland and Richard M Scearce and Barton F. Haynes},
  journal={Journal of virology},
  year={2004},
  volume={78 10},
  pages={5270-8}
}
One strategy for the generation of broadly reactive neutralizing antibodies (NA) against human immunodeficiency virus type 1 (HIV-1) primary isolates is to use immunogens that have constrained HIV-1 envelope gp120 conformations reflective of triggered envelope on the surface of virions. A major change in gp120 following binding to CD4 is the enhanced exposure of the CCR5 binding site. One inducer of CCR5 binding site epitopes on gp120 is the human anti-gp120 monoclonal antibody, A32. We have… CONTINUE READING